Risvodetinib, an experimental therapy that Inhibikase Therapeutics is developing for Parkinson’s disease, was well tolerated both by healthy volunteers and Parkinson’s patients in a Phase 1 clinical trial. That’s according to the full results from the Inhibikase-funded work, detailed in a study titled “A Phase I, Randomized,…
Researchers from a university in Scotland were among the contributors to recent World Health Organization (WHO) guidelines outlining the most essential interventions in rehabilitation for 20 health conditions — including Parkinson’s disease — with high prevalence and elevated levels of associated disability. The WHO’s “Package of Interventions for Rehabilitation”…
Knight Therapeutics has entered into an exclusive license agreement with Amneal Pharmaceuticals giving it rights to apply for regulatory approval of IPX203 in Canada and across Latin America, and, if granted, to market the Parkinson’s disease treatment there. IPX203 is an investigational, extended-release oral formulation…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…
Being a caregiver for someone with Parkinson’s disease can be difficult, but for family members, providing care is not a burden, it’s a partnership, an opportunity to express their love. That’s according to interviews with 16 current and former Parkinson’s care partners. The findings were published in the…
A four-week exercise program to improve balance, directed by a smartphone app, can help older adults walk at a faster pace and correct their posture, a study has found, features that may help to prevent falls, a common complication of Parkinson’s disease. The app, being developed by scientists at…
A new study by scientists in Australia may be set to overturn more than a decade of thinking that the use of the KTP molecule could work as a treatment for Parkinson’s disease. Titled “Interaction of PINK1 with nucleotides and kinetin” and published in Scientific Advances,…
Led by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an international group of patients, researchers, and industry leaders has proposed a framework for defining and staging Parkinson’s disease based on its underlying biology rather than by hallmark disease symptoms. Called the neuronal alpha-synuclein disease integrated…
Scientists have proposed a new way to classify Parkinson’s disease based on biological changes associated with the disorder. “Without looking at the biology, you can’t get answers. And without answers, we won’t have much-needed breakthroughs in Parkinson’s,” Anthony Lang, MD, a researcher at the Krembil Brain Institute in Canada,…
Centogene and The Michael J. Fox Foundation (MJFF) are teaming up on a research project to investigate genetic risk factors for Parkinson’s disease, with a particular focus on GBA gene mutations. This project’s main goal is to better understand how certain variations in the GBA gene are connected…
Get regular updates to your inbox.
